GSK Bets $950M on a Next-Gen Pulmonary Hypertension Therapy

GSK Bets $950M on a Next-Gen Pulmonary Hypertension Therapy

By, Admin 16 April 2026

Big pharma doesn’t spend nearly a billion dollars on a hunch. When GSK plc acquired 35Pharma Inc. for $950 million, it was making a calculated bet—on a single molecule: HS235. Here’s why that matters.

The Problem: Pulmonary Hypertension Is Still a High-Risk Disease

Pulmonary hypertension (PH) is not rare. It’s under-treated.

  • Affects ~82 million people globally
  • Progressive and life-shortening
  • ~50% five-year survival rate
  • Limited treatment options

Two major forms dominate clinical focus:

  • Pulmonary arterial hypertension (PAH)
  • PH linked to heart failure with preserved ejection fraction (PH-HFpEF)

Despite advances, current therapies struggle with safety limitations and inconsistent outcomes.

The Asset: HS235 and a Validated Pathway

At the center of the acquisition is HS235. This is not just another molecule. It targets the activin receptor signalling pathway, a clinically validated mechanism in PH. Why this matters:

  • Activin signalling inhibitors are expected to drive ~50% of an $18 billion PH market by 2032
  • The pathway is already proven—but not perfected

HS235 aims to improve on what exists.

What Makes HS235 Different?

Current PH therapies often come with trade-offs. Think:

  • Bleeding risks
  • Pericardial effusion
  • Increased haemoglobin levels

HS235 is designed to reduce these issues.

Key differentiators:

  • Enhanced selectivity
  • Reduced interaction with BMP9 and BMP10 (linked to adverse events)
  • Potentially safer for patients on anticoagulants or antiplatelet therapy

In simple terms: same pathway, fewer compromises.

The Hidden Angle: Metabolic Benefits

Here’s where things get interesting. Early clinical signals suggest HS235 may go beyond treating PH. Potential additional benefits:

  • Fat-selective weight loss
  • Preservation of lean muscle mass
  • Improved insulin sensitivity

If validated, this opens a second front: metabolic health.

Why that matters:

  • Obesity and insulin resistance are common in PH patients
  • A dual-benefit drug increases both clinical value and market potential

This is how one molecule becomes a platform play.

Strategic Fit: Strengthening GSK’s Pipeline

For GSK, this isn’t an isolated move. HS235 fits directly into its Respiratory, Immunology & Inflammation (RI&I) portfolio. According to Kaivan Khavandi, GSK’s R&D head for RI&I:

HS235 strengthens the company’s push into inflammatory and fibrotic disease drivers. Translation: GSK is building a mechanism-driven pipeline, not just a product portfolio.

What Happens Next?

The deal is done. Now execution begins. Immediate next steps:

  • Proof-of-concept trials launching soon
  • Focus on:
    • PAH
    • PH-HFpEF

If early trials validate safety and efficacy, HS235 could quickly move up the clinical ladder.

Market Context: A High-Stakes Opportunity

The PH market is evolving fast. Projected to hit $18 billion by 2032

  • Shift toward mechanism-specific therapies
  • Increasing demand for safer long-term treatments

GSK isn’t entering early—but it may be entering smarter.

Final Take

This acquisition checks three critical boxes:

  1. Validated biology (activin signalling)
  2. Differentiated design (better safety profile)
  3. Expansion potential (metabolic benefits)

If HS235 delivers in trials, GSK didn’t just buy a drug. It bought optionality across multiple disease pathways. And in pharma, that’s where the real value lies.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!